# ClinicalTrials.gov record NCT07225686

> PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07225686-maridebart-cafraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07225686-maridebart-cafraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07225686-maridebart-cafraglutide-v1.json
- Content SHA-256: `e40e8bba97f975587deebc29a5b115b4d7412329e779eba34e8a53df2f8938ee`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT07225686 ([`ctg-observation-nct07225686-2026-06-12-50c5d117af0d`](#source-ctg-observation-nct07225686-2026-06-12-50c5d117af0d))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07225686-2026-06-12-50c5d117af0d`](#source-ctg-observation-nct07225686-2026-06-12-50c5d117af0d))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07225686 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide. ([`ctg-observation-nct07225686-2026-06-12-50c5d117af0d`](#source-ctg-observation-nct07225686-2026-06-12-50c5d117af0d))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07225686-2026-06-12-50c5d117af0d`](#source-ctg-observation-nct07225686-2026-06-12-50c5d117af0d))

## Sources

<a id="source-ctg-observation-nct07225686-2026-06-12-50c5d117af0d"></a>
- **ClinicalTrials.gov record NCT07225686 · retained source version 2026-06-12:50c5d117af0dc48b2dd50fb0b65e9d36906883af0c94c88c6c3b44d9da0c56f5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07225686) (`ctg-observation-nct07225686-2026-06-12-50c5d117af0d`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07225686." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct07225686-maridebart-cafraglutide-v1.json SHA-256: e40e8bba97f975587deebc29a5b115b4d7412329e779eba34e8a53df2f8938ee.